Sage Therapeutics surges on postpartum depression drug study

July 12, 2016

A drug to treat severe postpartum depression showed positive results in a mid-stage study, sending shares developer Sage Therapeutics skyrocketing Tuesday.

There are no that specifically treat a type of depression that, according to the American Psychological Association, afflicts up to one in seven women who give birth.

The Sage was given to 10 patients and 11 others received a placebo. The company says that 60 hours after treatment, the women who took its drug had a significant reduction in their scores on a survey that is used to measure levels of depression. The patients who got the drug also had lower reading at the end of the 30-day study.

All of the patients in the study had had a child less than six months earlier, and they had suffered at least one episode of late in pregnancy or within a month of giving birth.

Postpartum depression includes feelings of extreme sadness, anxiety and exhaustion that can make it hard for new mothers to care for themselves or others, according to The National Institutes of Mental Health

Seven of the 10 patients who got the drug from Sage were in remission from their at 60 hours, according to the company. That compares with only one of the 11 placebo patients.

Sage Therapeutics doesn't have any drugs on the market. The drug in its most recent study is called SAGE-547, and Sage is conducting late-stage tests of the same drug as a treatment for a rare seizure disorder. It's further away from approval as a treatment for . SAGE-547 is given intravenously and the Cambridge, Massachusetts, company said Tuesday that it will speed up work on an oral version of the drug.

Shares of Sage Therapeutics jumped almost 40 percent, or $12.87, to $46.42 in early trading.

Explore further: Postpartum depression least severe form of depression in mothers

Related Stories

Postpartum depression least severe form of depression in mothers

June 15, 2016
Postpartum depression—a household term since actress Brooke Shields went public in 2005 about her struggle with it—is indeed serious. But depression that begins before or during pregnancy is often more severe because ...

Postpartum depression: what you need to know

November 9, 2015
The birth of a baby is supposed to be a time of wonder, joy and happiness. But for some new moms, that time can be one of sadness and anxiety. Mayo Clinic certified nurse-midwife Julie Lamppa says 80 percent of new moms experience ...

Antidepressant does not reduce hospitalization, death for HF patients with depression

June 28, 2016
In a study appearing in the June 28 issue of JAMA, Christiane E. Angermann, M.D., of University Hospital Wurzburg, Germany, and colleagues examined whether 24 months of treatment with the antidepressant escitalopram would ...

FDA approves new drug for schizophrenia, major depression

July 13, 2015
(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

Drug used for pain, anxiety may be linked to birth defects

May 18, 2016
A drug commonly used to treat pain, epilepsy, anxiety and other brain health disorders may be associated with an increased risk of major birth defects, according to a study published in the May 18, 2016, online issue of Neurology, ...

Oxytocin level in pregnancy predicts postpartum depression severity

March 23, 2016
Higher oxytocin levels in the third trimester of pregnancy predicts the severity of postpartum depression symptoms in women who previously suffered from depression, reports a new Northwestern Medicine study.

Recommended for you

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.